Is major pathologic response sufficient to predict survival in resectable nonsmall‐cell lung cancer patients receiving neoadjuvant chemotherapy?
Abstract Background Major pathologic response (MPR) is mainly focused on residual viable tumor in the tumor bed regardless of lymph node. Herein, we investigated the predictive value of MPR and node status on survival in nonsmall‐cell lung cancer (NSCLC) patients receiving neoadjuvant chemotherapy (...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-05-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.13903 |
| _version_ | 1818961916895166464 |
|---|---|
| author | Jing‐Sheng Cai Shuo Li Shu‐Mei Yan Jie Yang Mu‐Zi Yang Chu‐Long Xie Ji‐Bin Li Yan‐Fen Feng Hao‐Xian Yang Xue Hou |
| author_facet | Jing‐Sheng Cai Shuo Li Shu‐Mei Yan Jie Yang Mu‐Zi Yang Chu‐Long Xie Ji‐Bin Li Yan‐Fen Feng Hao‐Xian Yang Xue Hou |
| author_sort | Jing‐Sheng Cai |
| collection | DOAJ |
| description | Abstract Background Major pathologic response (MPR) is mainly focused on residual viable tumor in the tumor bed regardless of lymph node. Herein, we investigated the predictive value of MPR and node status on survival in nonsmall‐cell lung cancer (NSCLC) patients receiving neoadjuvant chemotherapy (NAC) and surgery. Methods A total of 194 eligible cases were included. Tumor pathologic response and node status were assessed. Based on these evaluations, patients were divided into the MPR group and the non‐MPR group, the nodal downstaging (ND) group and non‐ND group. Furthermore, patients were assigned into four subgroups (MPR + ND, MPR + non‐ND, non‐MPR + ND, and non‐MPR + non‐ND). Overall survival (OS) and disease‐free survival (DFS) were compared between groups. Multivariate analyses were performed to identify prognostic factors. Results MPR was identified in 32 patients and ND was present in 108 patients. OS and DFS were better in the MPR group than in the non‐MPR group, but with no statistical significance (OS, p = 0.158; DFS, p = 0.126). The ND group had better OS than the non‐ND group (p = 0.031). However, the DFS between these two groups was comparable (p = 0.103). Further analyses suggested that both OS and DFS were better in the MPR + ND group than in the non‐MPR + non‐ND group (OS, p = 0.017; DFS, p = 0.029). Multivariate analyses confirmed that MPR + ND was an independent favorable predictor. Conclusions MPR combined with ND could improve the predictive value on survival in NSCLC patients receiving NAC. |
| first_indexed | 2024-12-20T12:21:02Z |
| format | Article |
| id | doaj.art-887a0f5f490c4071bcb069286faa497d |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-12-20T12:21:02Z |
| publishDate | 2021-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-887a0f5f490c4071bcb069286faa497d2022-12-21T19:40:59ZengWileyThoracic Cancer1759-77061759-77142021-05-011291336134610.1111/1759-7714.13903Is major pathologic response sufficient to predict survival in resectable nonsmall‐cell lung cancer patients receiving neoadjuvant chemotherapy?Jing‐Sheng Cai0Shuo Li1Shu‐Mei Yan2Jie Yang3Mu‐Zi Yang4Chu‐Long Xie5Ji‐Bin Li6Yan‐Fen Feng7Hao‐Xian Yang8Xue Hou9Department of Thoracic Surgery Sun Yat‐sen University Cancer Center Guangzhou ChinaDepartment of Thoracic Surgery Sun Yat‐sen University Cancer Center Guangzhou ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou ChinaDepartment of Thoracic Surgery Sun Yat‐sen University Cancer Center Guangzhou ChinaDepartment of Thoracic Surgery Sun Yat‐sen University Cancer Center Guangzhou ChinaDepartment of Thoracic Surgery Sun Yat‐sen University Cancer Center Guangzhou ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou ChinaDepartment of Thoracic Surgery Sun Yat‐sen University Cancer Center Guangzhou ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou ChinaAbstract Background Major pathologic response (MPR) is mainly focused on residual viable tumor in the tumor bed regardless of lymph node. Herein, we investigated the predictive value of MPR and node status on survival in nonsmall‐cell lung cancer (NSCLC) patients receiving neoadjuvant chemotherapy (NAC) and surgery. Methods A total of 194 eligible cases were included. Tumor pathologic response and node status were assessed. Based on these evaluations, patients were divided into the MPR group and the non‐MPR group, the nodal downstaging (ND) group and non‐ND group. Furthermore, patients were assigned into four subgroups (MPR + ND, MPR + non‐ND, non‐MPR + ND, and non‐MPR + non‐ND). Overall survival (OS) and disease‐free survival (DFS) were compared between groups. Multivariate analyses were performed to identify prognostic factors. Results MPR was identified in 32 patients and ND was present in 108 patients. OS and DFS were better in the MPR group than in the non‐MPR group, but with no statistical significance (OS, p = 0.158; DFS, p = 0.126). The ND group had better OS than the non‐ND group (p = 0.031). However, the DFS between these two groups was comparable (p = 0.103). Further analyses suggested that both OS and DFS were better in the MPR + ND group than in the non‐MPR + non‐ND group (OS, p = 0.017; DFS, p = 0.029). Multivariate analyses confirmed that MPR + ND was an independent favorable predictor. Conclusions MPR combined with ND could improve the predictive value on survival in NSCLC patients receiving NAC.https://doi.org/10.1111/1759-7714.13903major pathologic responsenodal downstagingnon small‐cell lung cancer |
| spellingShingle | Jing‐Sheng Cai Shuo Li Shu‐Mei Yan Jie Yang Mu‐Zi Yang Chu‐Long Xie Ji‐Bin Li Yan‐Fen Feng Hao‐Xian Yang Xue Hou Is major pathologic response sufficient to predict survival in resectable nonsmall‐cell lung cancer patients receiving neoadjuvant chemotherapy? Thoracic Cancer major pathologic response nodal downstaging non small‐cell lung cancer |
| title | Is major pathologic response sufficient to predict survival in resectable nonsmall‐cell lung cancer patients receiving neoadjuvant chemotherapy? |
| title_full | Is major pathologic response sufficient to predict survival in resectable nonsmall‐cell lung cancer patients receiving neoadjuvant chemotherapy? |
| title_fullStr | Is major pathologic response sufficient to predict survival in resectable nonsmall‐cell lung cancer patients receiving neoadjuvant chemotherapy? |
| title_full_unstemmed | Is major pathologic response sufficient to predict survival in resectable nonsmall‐cell lung cancer patients receiving neoadjuvant chemotherapy? |
| title_short | Is major pathologic response sufficient to predict survival in resectable nonsmall‐cell lung cancer patients receiving neoadjuvant chemotherapy? |
| title_sort | is major pathologic response sufficient to predict survival in resectable nonsmall cell lung cancer patients receiving neoadjuvant chemotherapy |
| topic | major pathologic response nodal downstaging non small‐cell lung cancer |
| url | https://doi.org/10.1111/1759-7714.13903 |
| work_keys_str_mv | AT jingshengcai ismajorpathologicresponsesufficienttopredictsurvivalinresectablenonsmallcelllungcancerpatientsreceivingneoadjuvantchemotherapy AT shuoli ismajorpathologicresponsesufficienttopredictsurvivalinresectablenonsmallcelllungcancerpatientsreceivingneoadjuvantchemotherapy AT shumeiyan ismajorpathologicresponsesufficienttopredictsurvivalinresectablenonsmallcelllungcancerpatientsreceivingneoadjuvantchemotherapy AT jieyang ismajorpathologicresponsesufficienttopredictsurvivalinresectablenonsmallcelllungcancerpatientsreceivingneoadjuvantchemotherapy AT muziyang ismajorpathologicresponsesufficienttopredictsurvivalinresectablenonsmallcelllungcancerpatientsreceivingneoadjuvantchemotherapy AT chulongxie ismajorpathologicresponsesufficienttopredictsurvivalinresectablenonsmallcelllungcancerpatientsreceivingneoadjuvantchemotherapy AT jibinli ismajorpathologicresponsesufficienttopredictsurvivalinresectablenonsmallcelllungcancerpatientsreceivingneoadjuvantchemotherapy AT yanfenfeng ismajorpathologicresponsesufficienttopredictsurvivalinresectablenonsmallcelllungcancerpatientsreceivingneoadjuvantchemotherapy AT haoxianyang ismajorpathologicresponsesufficienttopredictsurvivalinresectablenonsmallcelllungcancerpatientsreceivingneoadjuvantchemotherapy AT xuehou ismajorpathologicresponsesufficienttopredictsurvivalinresectablenonsmallcelllungcancerpatientsreceivingneoadjuvantchemotherapy |